Skip to main content
Monday, November 16, 2026Nov 16

Last drugs standing: Key Alzheimer results coming

photo Gammagard is a treatment that is being tested for Alzheimer’s disease. Three treatments, including Bapineuzumab and Solanezumab, are being tested for the disease are antibodies – proteins made by the immune system that promote clearance of amyloid, the stuff that forms the plaque.

By MARILYNN MARCHIONE

AP Chief Medical Writer

We’re about to find out if there will be a way anytime soon to slow the course of Alzheimer’s disease. Results are due within a month or so from key studies of two drugs that aim to clear the sticky plaque gumming up patients’ brains.

A pivotal study of a third drug will end later this year, and results from a small, early test of it will be reported next week at an Alzheimer’s conference in Vancouver, British Columbia.

These three treatments are practically the “last men standing” in late-stage trials, after more than a decade of failed efforts to develop a drug to halt the mind-robbing disease. Current medicines such as Aricept and Namenda just temporarily ease symptoms. There is no known cure.